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Abstract
Background: Neuropathic pain is evasive to treat once developed, however evidence suggests that local administration
of anesthetics near the time of injury reduces the development of neuropathic pain. As abnormal electrical signaling in
the damaged nerve contributes to the initiation and maintenance of neuropathic pain, local administration of anesthetics
prior to injury may reduce its development. We hypothesized that local treatment with bupivacaine prior to nerve injury
in a rat model of spinal nerve ligation (SNL) would attenuate the initiation and/or maintenance of neuropathic
pain behaviors.
Methods: On the day prior to SNL, baseline measures of pre-injury mechanical, thermal, and/or cold sensitivity
were recorded in adult male Sprague–Dawley rats. Immediately prior to SNL or sham treatment, the right L5
nerve was perineurally bathed in either 0.05 mL bupivacaine (0.5 %) or sterile saline (0.9 %) for 30 min. Mechanical
allodynia, thermal hyperalgesia, and/or cold allodynia were then examined at 3, 7, 10, 14 and 21 days following SNL.
Results: Rats exhibited both mechanical and cold allodynia, but not thermal hyperalgesia, within 3 days and up to
21 days post-SNL. No significant pain behaviors were observed in sham controls. Preemptive local bupivacaine
significantly attenuated both mechanical and cold allodynia as early as 10 days following SNL compared to saline
controls and were not significantly different from sham controls.
Conclusions: These data indicate that local treatment with bupivacaine prior to surgical manipulations that are known
to cause nerve damage may protect against the maintenance of chronic neuropathic pain.
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Background
It is estimated that 100 million Americans suffer from
chronic pain [1]. Chronic neuropathic pain is a common
complication that develops in many patients following
surgery involving intraoperative nerve damage [2].
Military Service Members represent a subset of the
population that is especially at risk. Approximately 44 %
of the Service Members deployed to either Iraq or
Afghanistan [3] and over 80 % of veterans report chronic
pain [4]. Over half sustain injuries involving nerve dam-
age, such as motor vehicle accidents, blasts and burns,
and lower back injuries [5–7]. A subset is subject to
amputations, nerve dissections and invasive surgeries in-
volving further nerve damage that may exacerbate the
development of neuropathic pain [8]. As neuropathic
pain is elusive to treat after it has developed, treatment
strategies that effectively reduce the incidence of neuro-
pathic pain are desired.
Electrical hyperexcitability and abnormal nerve pulse
generation occur in injured sensory neurons [9–11]. The
behavioral hallmark of this altered neuronal signaling is
abnormal responsiveness to non-noxious stimuli, termed
allodynia. Preclinical research indicates that if early
spontaneous afferent activity following nerve damage is
blocked by local anesthetics, allodynia may not develop
[12]. This report, along with others using a range of
neuropathic pain models [12–15], indicates a critical
treatment window to reduce the probability of
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developing a chronic neuropathic pain condition. An at-
tempt at local anesthesia during or immediately following
injury has been postulated as a treatment strategy. Indeed,
a recent advance in pain management in wounded Service
Members is the use of regional anesthesia on the battle-
field [16–18].
Many studies have characterized the effects of anes-
thetics on treatment immediately following nerve damage,
as treatment is often sought following injury. However,
local preemptive anesthetic treatment may be applied in
instances where nerve damage is imminent, such as inva-
sive surgery or amputation, however the effects of preemp-
tive versus postoperative analgesia on the development of
chronic neuropathic pain are unclear [19]. It may be pos-
sible to directly prevent various changes in primary affer-
ents, spinal sites and descending modulation prior to nerve
insult. In support, preemptive blockade of peripheral affer-
ent firing prior to oral surgery significantly reduces pain
ratings and central sensitization 48 h following surgery
[20]. It is then possible that preemptive local anesthetic
treatment can prevent the development of chronic neuro-
pathic pain conditions.
The anesthetic bupivacaine blocks nerve impulses by
binding to the intracellular portion of voltage-gated so-
dium channels to prevent depolarization and is currently
approved for clinical use as a long-duration peripheral
nerve block [21]. We hypothesized that local preemptive
bupivacaine treatment prior to nerve injury in a rat
model of spinal nerve ligation (SNL) would attenuate
the initiation and/or maintenance of neuropathic pain
behaviors. Our results provide preclinical evidence of
the analgesic effect of a single perineural application of
bupivacaine prior to nerve injury on neuropathic pain
outcomes over 3 weeks post-SNL. Bupivacaine used as a
preemptive treatment may prevent or attenuate the oc-
currence of chronic neuropathic pain conditions in
Service Members and other patient populations.
Methods
Subjects
A total of 44 adult (200–300 g) intact male Sprague–
Dawley rats (Charles River Laboratories, Wilmington,
MA, USA) were used in these experiments. Rats were
pair housed in a 12:12 h light:dark cycle with ad libi-
tium access to food and water. All studies were ap-
proved by the U.S. Army Institute of Surgical
Research Institutional Animal Care and Use Commit-
tee and conform to federal guidelines and guidelines
of the International Association for the Study of Pain.
This study was conducted in strict compliance with
the Animal Welfare Act, implementing Animal Wel-
fare Regulations, and the principles of the Guide for
the Care and Use of Laboratory Animals. The animal
facility is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal
Care, International (AAALAC, Intl.).
Drugs
Forane (isoflurane, USP) was purchased from Baxter
Healthcare (Deerfield, IL, USA) for use as volatile gas
anesthesia (3 % for induction; 2–2.5 % for maintenance).
Bupivacaine hydrochloride, USP (5 mg/mL; 0.5 %) was
purchased from Hospira (Lake Forest, IL, USA).
Spinal nerve ligation and preemptive bupivacaine treatment
Animals were anesthetized with isoflurane delivered via a
rat-specific nose cone and placed in the prone position.
The paraspinal muscles were separated from the spinous
processes at the L4-S2 levels. The right L6 transverse
process was removed to allow identification of the L4 and
L5 spinal nerves. Prior to ligation, the right L5 spinal
nerve was bathed in either 0.05 mL bupivacaine (n = 16)
or 0.9 % sterile saline (n = 16), by pipetting directly onto
the exposed nerve, and allowed to remain for 30 min be-
fore ligation occurred. A non-absorbable 6–0 silk suture
was then tied around the right L5 spinal nerve, being care-
ful not to damage L4, as previously characterized [22].
The fascia was sutured using 3–0 silk suture and the skin
closed with wound clips. Silver sulfadiazine ointment (1 %;
Watson) was applied to the incision site immediately fol-
lowing surgery. Sham animals (n = 12) received all the
same surgical manipulations without the actual tying of
the ligation. Rats were allowed to recover for 3 days prior
to behavior testing.
Mechanical allodynia
To measure changes in sensitivity thresholds to non-
noxious mechanical stimulus, 23 rats (n = 8 SNL and
saline treated; n = 8 SNL and bupivacaine treated; n = 7
sham) were acclimated to the testing apparatus for
20 min. A Dynamic Plantar Aesthesiometer (Ugo
Basile; Collegeville, PA, USA) was used to assess the
force (in grams) required to elicit a paw withdrawal
from a blunt mechanical stimulus, as previously de-
scribed [23]. For this test, rats were placed in a Plexi-
glass box on an elevated grid platform and a blunt
mechanical probe was aimed at the base of the third
and fourth toe on the hindpaw (Fig. 1b). This location
was chosen based on previous reports that the highest
sensitivity to mechanical stimuli following SNL is ob-
served at this location [24]. The force of the mechanical
stimulus was increased with a ramp of 3 g/s over 10 s
with a cutoff of 30 g to avoid mechanical lifting of the
paw by the device. The average force required to elicit
a paw withdraw over 3 trials was recorded. Baseline
measurements of force required to elicit paw with-
drawal from both the ipsilateral and contralateral
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hindpaws were recorded 24 h prior to nerve ligation as
a measure of pre-injury mechanical sensitivity. Mech-
anical allodynia was then assessed at 3, 7, 10, 14 and
21 days following spinal nerve ligation (Fig. 1a). This
time course was chosen based on previous reports
[22, 25]. The behavioral analyst was blinded to the
experimental group of each animal tested.
Thermal hyperalgesia
A subset of the same rats used to examine mechanical
allodynia were also used to examine changes in sensitivity
thresholds to a noxious thermal stimulus (n = 6 SNL and
saline treated; n = 7 SNL and bupivacaine treated; n = 3
sham). Paw withdrawal latencies to a thermal stimulus
were determined using the Plantar Test Apparatus
(Hargreaves Method, IITC) as previously described [26].
For this test, rats were placed in a clear Plexiglass box
resting on an elevated glass plate and allowed to acclimate
for 20 min. A radiant beam of light was then aimed at the
plantar surface of the hindpaw and the average paw with-
drawal latency over 3 trials was recorded. Baseline mea-
surements of paw withdrawal in seconds from both the
ipsilateral and contralateral hindpaws were recorded 24 h
prior to nerve ligation as a measure of pre-injury thermal
sensitivity. Thermal hyperalgesia was then assessed at
3, 7, 10, 14 and 21 days following nerve ligation. A
period of 4 h was retained between mechanical allody-
nia and subsequent thermal hyperalgesia testing to
prevent behavioral sensitization of paw withdrawal
responses to the stimuli.
Cold allodynia
A separate group of rats was used to examine noci-
fensive behaviors to a cold stimulus. Rats (n = 8 SNL
and saline treated; n = 8 SNL and bupivacaine treated;
n = 5 sham) were placed in a Plexiglass box resting
on an elevated grid platform and a stream of either
100 μL acetone (Fisher Scientific) or 0.9 % sterile sa-
line (room temperature) was applied to the plantar
surface of the hindpaw, as previously described [27].
The number of shakes and/or licking episodes of the
ipsilateral and contralateral hindpaws due to the cool-
ing evoked by acetone evaporation [28] was measured
over a 2 min observation period. The mean of 2 con-
secutive trials with a 5 min interval was calculated as
a measure of nocifensive behavior to a cold stimulus.
Cold allodynia was then assessed at 3, 7, 10, 14 and
21 days following spinal nerve ligation.
Statistical analysis
Data are expressed as mean ± standard error of the
mean force to withdrawal in grams, paw withdrawal
latencies in seconds, or number of nocifensive re-
sponses to acetone application. Data were analyzed by
two-way repeated measures ANOVA across all time
points. Individual groups were compared using
Tukey’s multiple comparisons post hoc analysis. The
statistical significance was tested at p < 0.05. All data
were analyzed using GraphPad Prism software version
6 (GraphPad).
Fig. 1 Experimental Design. Timeline illustrating the experimental design by day pre- or post-spinal nerve ligation surgery (a). Image illustrates as
marked by X the location of application of the non-noxious mechanical, noxious thermal, and non-noxious cold stimuli at the plantar surface of
the rat hindpaw (b)
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Results
All rats were acclimated to the testing apparatuses two
days prior to spinal nerve ligation. Baseline measures of
mechanical, thermal, and/or cold sensitivity were re-
corded 24 h prior to SNL (Fig. 1a) to determine pre-
injury thresholds. To examine changes in sensitivity,
non-noxious mechanical, noxious thermal and non-
noxious cold stimuli were applied to the mid-plantar
surface (Fig. 1b) of the right (ipsilateral) and left (contra-
lateral) hindpaws. SNL-evoked neuropathic pain behav-
iors were examined on 3, 7, 10, 14 and 21 days following
preemptive local treatment (bupivacaine, saline, sham).
There was a significant main effect of treatment
[F(2,20) = 16.91; p < 0.0001] and time post-injection
from baseline [F(5100) = 12.52; p < 0.0001] on the
degree of SNL-evoked mechanical allodynia.
In rats that received a 30-min perineural application of
saline at the L5 spinal nerve prior to nerve ligature, the
ipsilateral hindpaw displayed significant mechanical allo-
dynia within 3 days and lasting up to 21 days compared
to sham controls and baseline (Fig. 2a). In rats that re-
ceived a preemptive 30-min perineural application of
bupivacaine, mechanical allodynia was significantly at-
tenuated at 10, 14 and 21 days following SNL as com-
pared to saline treated controls (Fig. 2a). Furthermore,
there was a significant interaction of treatment over time
from baseline [F(10,100) = 2.94; p = 0.0028]. The 3, 7 and
10 day time points were significantly lower than base-
lines (p < 0.05), however the 14 and 21 day time points
were not significantly different from baseline (p > 0.05).
All time points following saline treatment were signifi-
cantly lower than baseline measures (p < 0.05). Mechan-
ical allodynia in rats treated with bupivacaine was not
significantly different from sham controls as early as
7 days post-SNL (p > 0.05). There was no significant
main effect of time [F(5100) = 1.26; p = 0.29] or treat-
ment [F(2,20) = 0.48; p = 0.62] in the contralateral hind-
paw (Fig. 2b).
Thermal hyperalgesia involves distinct pain process-
ing that may be differentiated from mechanical allody-
nia [29, 30]. A subset of rats that were tested for
mechanical allodynia were also tested for changes in
thermal sensitivity before and following bupivacaine or
saline application prior to SNL or sham treatment.
There was no significant main effect of treatment
[F(2,12) = 2.78; p = 0.10] or time post-injection [F(4,48)
= 0.37; p = 0.83] on thermal hyperalgesia following SNL.
In rats that received a 30-min perineural application of
saline, there was no significant change in thermal
thresholds in the ipsilateral hindpaw at any time points
tested compared to sham controls (Fig. 3a). In rats that
received a preemptive 30-min perineural application of
bupivacaine, there was no significant change from basal
thermal sensitivity in the ipsilateral paw (Fig. 3a).
Furthermore, there was no significant main effect of
treatment [F(2,11) = 0.97; p = 0.41] or time post-
injection from baseline [F(4,44) = 0.92; p = 0.46] in the
contralateral hindpaw (Fig. 3b).
A separate group of rats was used to next examine the
effect of preemptive bupivacaine on the incidence of
neuropathic cold allodynia. Changes in cold sensitivity
were detected as nocifensive behaviors following acetone
application to the hindpaw. There was a significant main
effect of treatment [F(2,18) = 6.39; p = 0.008] and time
post-injection from baseline [F(5,90) = 8.05; p < 0.0001] on
the degree of SNL-evoked cold allodynia. In rats that re-
ceived a 30-min perineural application of saline at the L5
spinal nerve prior to nerve ligature, the ipsilateral hindpaw
displayed significant cold allodynia within 3 days following
spinal nerve ligation and lasting through 21 days compared
to sham controls (Fig. 4a). In rats that received a preemp-
tive 30-min perineural application of bupivacaine, cold
Fig. 2 Preemptive bupivacaine attenuates mechanical allodynia evoked
by spinal nerve ligation. Force in grams required to elicit hindpaw
withdrawal from a non-noxious mechanical stimulus applied to the
ipsilateral (a) and contralateral (b) hindpaw. Responses were recorded
prior to and 3, 7, 10, 14 and 21 days following bupivacaine (n = 8)
or saline (n = 8) treatment prior to spinal nerve ligation. A sham (n = 7)
group was also tested. Asterisks denote significant main effect of
treatment detected by two-way ANOVA and Tukey’s posthoc
analysis. * denotes significance from saline treated at p < 0.05; # denotes
significance from baseline at p < 0.05
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allodynia was significantly attenuated at 10 and 14 days fol-
lowing SNL as compared to saline treated controls (Fig. 4a).
Cold allodynia in rats treated with bupivacaine was not sig-
nificantly different from sham controls at all time points
tested (p > 0.05). Furthermore, there was a significant inter-
action of treatment over time [F(10,90) = 1.94; p = 0.05].
Cold allodynia was significantly greater than baseline mea-
sures on days 3 and 7 following SNL (p < 0.05), however
the 10, 14 and 21 day time points were not significantly dif-
ferent from baseline (p > 0.05). There was a significant
main effect of time post-injection [F(5,90) = 4.16; p =
0.002], but not treatment [F(2,18) = 1.20; p = 0.32] of cold
allodynia in the contralateral hindpaw (Fig. 4b). However,
there was no significant interaction of treatment over time
in the contralateral paw [F(10,90) = 0.75; p = 0.68].
Discussion
Pain associated with neuropathies is often difficult to
manage effectively as the mechanisms involved in the
initiation and maintenance of neuropathic pain remain
unclear. Nerve damage evokes electrical hyperexcitability
and abnormal nerve pulse generation that develops in
primary sensory neurons with damaged afferents [31]
and progresses to changes in spinal and supraspinal pain
processing [8]. The consequence of these anatomical al-
terations could include the development of chronic pain
conditions affecting both injured and uninjured areas
through the process of central sensitization [32, 33]. The
Neuropathic Pain Special Interest Group of the Inter-
national Association for the Study of Pain released a
consensus report recommending ion channel blockers as
a first-line treatment for neuropathic pain [34].
Clinical studies have reported that local anesthetic ion
channel blockers, such as lidocaine, may reduce neuro-
pathic pain [35, 36]. Preemptive lidocaine has been re-
ported to attenuate allodynia in a rat model of chronic
constriction injury (CCI) [14] and partial transection
neuropathy (PTN) [13], but not partial constriction
Fig. 3 No effect of spinal nerve ligation or bupivacaine on thermal
hyperalgesia. Paw withdrawal latency to a noxious thermal stimulus
applied to the ipsilateral (a) and contralateral (b) hindpaw. Responses
were recorded prior to and 3, 7, 10, 14 and 21 days following
bupivacaine (n = 7) or saline (n = 6) treatment prior to spinal nerve
ligation. A sham (n = 3) group was also tested. Asterisks denote
significant main effect of treatment detected by two-way ANOVA
and Tukey’s posthoc analysis
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Fig. 4 Preemptive bupivacaine attenuates acetone-induced cold
allodynia. The number of shakes and/or licking episodes of the
hindpaw following acetate application is reported as a measure
of nocifensive behavior to a cold stimulus. Acetone applied to
the ipsilateral (a) and contralateral (b) hindpaw. Responses were
recorded prior to and 3, 7, 10, 14 and 21 days following bupivacaine
(n = 8) or saline (n = 8) treatment prior to spinal nerve ligation. A sham
(n = 5) group was also tested. Asterisks denote significant main effect
of treatment detected by two-way ANOVA and Tukey’s posthoc analysis.
* denotes significance from saline treated at p < 0.05; # denotes
significance from baseline at p < 0.05
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neuropathy (PCN) [13]. However lidocaine is suboptimal
due to short-acting duration of effect and possible sys-
temic toxicity in large doses. This is problematic as
nerve injury evokes a significant increase in spontaneous
discharge in rat afferents within 24 h and is reduced
within 5 days [37], however neuropathic pain behaviors
often persist for weeks [38]. Furthermore, the effects of
preemptive local anesthetic remain unclear in preclinical
research due to the variability in findings between ani-
mal models of neuropathy.
In the present study, mechanical and cold allodynia
developed within 3 days following ligation of L5 using
the SNL model. Here we report that a single preemptive
perineural application of bupivacaine initially did not
block the onset of allodynia, but did attenuate mechan-
ical and cold allodynia as early as 7–10 days following
nerve injury. Mechanical allodynia was not significantly
different from uninjured sham controls as early as 7 days
following nerve injury, while cold allodynia did not differ
from sham controls at all time points observed. Indeed,
sham and bupivacaine treated rats were indistinguishable
by 2 weeks post-SNL. In contrast, Abdi et al. [15] re-
ported that local bupivacaine treatment was only effect-
ive at 24 h post-injury, but not at later time points up to
7 days. This discrepancy may be due to differences in se-
verity of ligation (ligation of both L5 and L6 vs only L5)
and/or timing of bupivacaine treatment (10 vs 30 min).
Furthermore, the present study did not analyze neuro-
pathic pain behaviors 24 h following injury. This is a
limitation to the current study as it is possible that a
transient effect could have occurred prior to 3 days post-
injury. While no overt differences between the two vari-
ants of the SNL model have been reported, it is more
probable that the duration of treatment accounts for this
discrepancy and remains to be addressed in further stud-
ies. Regardless, our findings mirror findings that have
been reported in clinical studies. In patients undergoing
third molar extractions, intraoral preemptive bupiva-
caine prior to surgery did not have a significant effect on
pain ratings at 24 h post-surgery, but bupivacaine treated
patients did report lower pain intensities at 48 h post-
surgery [20]. Similarly, our data showed that preemptive
local bupivacaine did not block the initial development
of pain behaviors, but did attenuate persistent allodynia.
Importantly, our data indicate that preemptive local
bupivacaine significantly shortened recovery time from
SNL-induced mechanical and cold allodynia, indicating
that bupivacaine may block the occurrence of some per-
sistent neuropathic pain conditions. These data are also
in agreement with a previous study reporting efficacy of
preemptive bupivacaine in a different nerve injury
model, the rat spared nerve injury (SNI) model [39]. To-
gether, these studies provide preclinical evidence in two
distinct neuropathic pain models that preemptive
perineural bupivacaine improves neuropathic pain out-
comes. Thus preemptive bupivacaine appears to be ef-
fective in some neuropathic pain models and not others
in reducing allodynia, mirroring opposing findings in
clinical studies. Further studies to determine whether
preemptive bupivacaine is effective in animal models of
chemotherapy-induced neuropathic pain (CINP) or
post-surgical pain, and as compared to other local anes-
thetics, are warranted.
Bupivacaine could be acting via (1) reducing ectopic
firing activity in primary afferent fibers, (2) reducing
central sensitization, and/or (3) altering descending fa-
cilitation, which is known to regulate the maintenance
of pain rather than its onset [8, 12]. Research indicates
discrete processes are involved in the onset versus main-
tenance of neuropathic pain. Burgess et al. [25] reported
that the initiation of neuropathic pain (days 0–3) is inde-
pendent of, but maintenance (days 6–12) is modulated
by, supraspinal influences. In support, ligation of seroto-
nergic descending pathways in the SNL model does not
affect the onset of mechanical hypersensitivity, but does
attenuate mechanical hypersensitivity one week later
(see review [8]). Thus one hypothesis is that preemptive
bupivacaine is acting in a manner that is preventing
supraspinal facilitation of neuropathic pain. This hypoth-
esis is supported by the differential effects of preemptive
bupivacaine on the onset versus maintenance of allody-
nia in the present study. Further studies examining rela-
tive alterations in ion channel expression and
electrophysiological or neurographical recordings are
warranted to provide insight into what anatomical
level(s) is being altered at 3 versus 7 days following pre-
emptive bupivacaine and nerve injury.
Xie et al. [12] reported that nerve blockade immedi-
ately following injury and lasting 3–5 days significantly
attenuated allodynia in the chronic constrictive injury
(CCI) and spared nerve injury (SNI) rat models of
neuropathic pain. In support, intercostal bupivacaine ad-
ministered prior to rat thoracotomy prevents the devel-
opment of pain behaviors in a greater number of
animals than post-surgical administration or when given
systemically before surgery [40]. This has also been ob-
served clinically in patients undergoing third molar sur-
gery [41] and knee ligament reconstruction [42]. One
clinical trial was able to compare preincisional to postin-
cisional treatment with mepivacaine and reported a sig-
nificant reduction in postoperative pain at 6 months
[43]. However studies have also reported no differences
in pain outcomes following pre- versus postoperative
treatment [44].
In the present study, SNL did not induce significant
thermal hyperalgesia when comparing SNL and sham
groups while mechanical and cold sensitivity were ro-
bust, in agreement with some studies [45–47] and
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discordant with others [12, 22, 25]. The reasons for this
difference are not discernable from the present study,
but are likely due to differences in weight-bearing of the
injured paw [45], test-dependent magnitude of thermal
sensitivity [29, 30, 48], and/or potential differences in
temporal presentation of thermal hyperalgesia or hypoal-
gesia [45, 49]. Despite these differences, the presence of
significant mechanical and cold allodynia provides a
clinically relevant neuropathic pain indicator in the
present study.
There are a variety of therapeutics targeting different
pain mechanisms that are used in clinical settings, how-
ever there is no one treatment that has proven effective
for neuropathic symptoms in all patients. Anticonvul-
sants such as gabapentin are also recommended [34],
presumably due to their ability to reduce calcium chan-
nel conductance. Gabapentin has been reported to be ef-
fective for pain associated with various peripheral
neuropathies in clinical trials [50, 51], but requires sev-
eral weeks of treatment before an attenuating effect is
observed. In preclinical studies, continuous infusion of
gabapentin for 7 days following injury was effective in
attenuating mechanical allodynia in rats [52]. Further-
more, perineural pregabalin treatment produced super-
ior analgesia compared to systemic administration [53].
Other ion channel blockers may also be effective for
the preemptive treatment of neuropathic pain. Blockade
of early spontaneous afferent activity with the sodium
channel blocker tetrodotoxin (TTX) following SNL also
suppresses neuropathic pain [12]. The blockade of sig-
naling by TTX was accompanied by reduced activation
of satellite glial cells in the dorsal root ganglia (DRG),
which could explain its analgesic effect as activated glial
cells play a central role in neuropathic pain [54, 55].
Ketamine exerts at least part of its analgesic effects
through antagonism of the N-Methyl-D-aspartate
(NMDA) receptor. As both a glutamate receptor and a
calcium ion channel, ketamine’s actions on NMDA re-
ceptors may be an effective preemptive analgesic for
neuropathic pain [56, 57]. Indeed, preemptive intrathecal
ketamine attentuates allodynia for 2 weeks following
nerve injury [58].
Conclusions
The postoperative pain that results from surgical nerve
damage has a profound impact on recovery and quality
of life and is a major clinical problem [8]. Our data pro-
vide preclinical evidence supporting the use of local pre-
emptive bupivacaine to attenuate the persistent
occurrence of allodynia following surgical manipulations
that are known to cause nerve damage, such as invasive
surgery, nerve dissection and amputations in the military
Service Member and civilian populations. The use of
preemptive local bupivacaine in patients undergoing
surgery, for example through ultrasound-guided paraver-
tebral injection [59], may shorten the recovery from
nerve injury-evoked mechanical and cold allodynia.
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